Anne‐Laure Chené

ORCID: 0000-0002-6916-7998
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Occupational and environmental lung diseases
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Tracheal and airway disorders
  • Immunotherapy and Immune Responses
  • Long-Term Effects of COVID-19
  • COVID-19 and healthcare impacts
  • COVID-19 and Mental Health
  • Pleural and Pulmonary Diseases
  • Polyomavirus and related diseases
  • Immune cells in cancer
  • Global Cancer Incidence and Screening
  • Intensive Care Unit Cognitive Disorders
  • Bacterial Infections and Vaccines
  • Phagocytosis and Immune Regulation
  • Medical Imaging and Pathology Studies
  • Multiple Sclerosis Research Studies
  • Viral-associated cancers and disorders
  • Effects of Radiation Exposure
  • Infectious Diseases and Tuberculosis
  • Airway Management and Intubation Techniques
  • Cancer Cells and Metastasis
  • Salivary Gland Tumors Diagnosis and Treatment

Nantes Université
2016-2024

Centre National de la Recherche Scientifique
2016-2024

Centre Hospitalier Universitaire de Nantes
2013-2024

Université d'Angers
2018-2024

Inserm
2016-2024

Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2016-2024

Institut du Thorax
2018-2023

Hôpital Laennec
2020

Hôpital Nord
2020

Background Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The tumor microenvironment content, particularly the presence of macrophages, was described as crucial for development disease. This work aimed at studying involvement M-CSF (CSF-1)/IL-34/CSF-1R pathway in formation macrophages MPM, using samples from patients. Methods Pleural effusions (PEs), frozen tumors, primary MPM cells cell lines used this study belong biocollections...

10.1136/jitc-2019-000182 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-06-01

COVID-19 sequelae are numerous and multisystemic, how to evaluate those symptomatic patients is a timely issue. Klok et al proposed the Post-COVID-19 Functional Status (PCFS) Scale as an easy tool limitations related persistent symptoms. Our aim was analyse PCFS ability detect functional its correlation with quality of life in cohort patients, 2-9 months after hospitalisation for hypoxemic pneumonia. evaluated 121 together dyspnoea questionnaires, pulmonary function tests CT scans. We...

10.1136/bmjresp-2021-001136 article EN cc-by-nc BMJ Open Respiratory Research 2022-03-01

Abstract Background Lung cancers represent the main cause of cancer related-death worldwide. Recently, immunotherapy alone or in combination with chemotherapy has deeply impacted therapeutic care leading to an improved overall survival. However, relapse will finally occur, no efficient second line treatment so far. New therapies development based on comprehension resistance mechanisms is necessary. difficulties obtain tumor samples before and after first hamper clearly understand consequence...

10.1186/s12931-024-02791-5 article EN cc-by Respiratory Research 2024-04-05

Introduction Interstitial lung diseases (ILDs) can be caused by mutations in the SFTPA1 and SFTPA2 genes, which encode surfactant protein (SP) complex SP-A. Only 11 or have so far been reported worldwide, of five functionally assessed. In framework ILD molecular diagnosis, we identified 14 independent patients with pathogenic mutations. The present study aimed to assess different accurately describe disease phenotype their affected relatives. Methods consequences were analysed both vitro ,...

10.1183/13993003.02806-2020 article EN European Respiratory Journal 2020-08-27

To evaluate the risk of pleural disorders (PD) associated with 33 protein kinase (PK) inhibitors (PKIs) through a disproportionality analysis and to identify which PKs pathways are involved in PKI-induced PD.To PD, reporting odds ratios (RORs) were calculated for PKIs data registered World Health Organization safety report database (VigiBase). We undertook literature review that possibly PD caused by PKIs. Pearson correlation coefficients (r) between RORs affinity 19 cellular target most...

10.1111/bcp.13693 article EN British Journal of Clinical Pharmacology 2018-06-26

<title>Abstract</title> <bold>Background</bold>: Lung cancer treatment is a constantly evolving field, with an acceleration of innovative therapies over the last decade. Patients included in clinical trials are highly selected, thus efficacy all comers still scarce. Despite significant progress, mortality remains high, disease progression occurs most patients, and mechanisms underlying resistance to remain poorly understood. The BREATHE project (Biocollection for Research Thoracic Cancer)...

10.21203/rs.3.rs-5667989/v1 preprint EN cc-by Research Square (Research Square) 2024-12-30

The consequences of the strict health restrictions during first wave COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated impact initial lockdown management and long-term outcome in LC patients. exposed-unexposed-type included two evaluation periods 6 months each non-selected patients; one began day 2020, other 2019 same calendar period. Various indicators were compared: clinical profiles, delays overall survival beyond 2 years. A total 816 from 7 public or...

10.3390/cancers15245729 article EN Cancers 2023-12-06

Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted a small percentage of patients. Thus, better understanding disease needed identify new strategies. Recently, interleukin 7 receptor (IL-7R) has been described as being expressed by MPM cells associated with poorer patient survival. aim this work was study IL-7R/IL-7 pathway in using samples....

10.1002/1878-0261.13310 article EN cc-by Molecular Oncology 2022-08-29
Coming Soon ...